Gregory P. Luib
Counsel | Washington, D.C.
Gregory P. Luib

Gregory P. Luib focuses his practice on antitrust and competition matters. Using his government and private sector experience, Mr. Luib represents clients in mergers and conduct investigations before the Federal Trade Commission (FTC) and Department of Justice (DOJ) and in private litigation, in a wide range of industries, including life sciences, health, and technology. Mr. Luib also represents clients in consumer protection matters before the FTC relating to advertising, marketing, privacy, and data security practices. Mr. Luib is listed in the Legal500 for Antitrust/Merger Control.

Mr. Luib served for more than a decade with the FTC. Most recently, as attorney advisor to Commissioner Maureen K. Ohlhausen, he provided counsel on competition matters, including merger and conduct investigations, law enforcement actions taken by the FTC, and significant issues of competition policy. Mr. Luib’s FTC experience also includes work as an attorney in the Mergers I Division of the Bureau of Competition, where he led merger investigations in various industries, including pharmaceuticals, health care data, industrial gases, aerospace, and defense. Mr. Luib previously served as the assistant director of the FTC’s Office of Policy Planning (OPP), where he focused on competition and consumer protection matters and served as a principal drafter of several policy reports issued by the Commission in the areas of network neutrality, Noerr-Pennington antitrust immunity, and real estate brokerage services. While in OPP, Mr. Luib received the Paul Rand Dixon award for outstanding contributions to the agency’s competition advocacy program.

Prior to joining the FTC in 2005, Mr. Luib was an associate at another international law firm where he focused his practice on merger review and antitrust counseling and litigation.

Mr. Luib is a frequent author and lecturer on antitrust issues in the healthcare, pharmaceuticals, and technology industries. Mr. Luib is also an active member of the ABA’s Section of Antitrust Law, where he currently serves as Co-Chair of Committee Operations. 

  • Guided CVS Health to antitrust approval for its $70 billion acquisition of Aetna, the largest healthcare services deal ever and the largest announced deal of 2017.
  • Advised a leading U.S. airline in regulatory proceedings before DOT and foreign competition authorities in connection with applications for antitrust immunity for joint business agreements with international partners.
  • Advised a medical device manufacturer in its acquisition by a competitor, avoiding an FTC second request in the process.
  • Represented a financial services company in an FTC consumer protection matter, convincing the agency to close its investigation.
  • Represented a consumer goods company in an FTC investigation into its U.S.-origin marketing claims, obtaining a closing letter from the agency.
  • Represented Procter & Gamble in its acquisition of Gillette.
  • Represented R.J. Reynolds in its acquisition of Brown & Williamson.
  • Represented Roadway Express in its acquisition of Yellow Transit.
  • Represented DIRECTV in its acquisiton by News Corp.
  • Represented Ultramar Diamond Shamrock in its acquisition by Valero Energy.
  • Represented Bayer in In re Ciprofloxacin Hydrochloride Antitrust Litigation, involving antitrust claims arising from the settlement of pharmaceutical patent litigation.

Includes matters handled at Dechert or prior to joining the firm.

  • Clash of the Global Titans: Privacy v. Competition — ABA Antitrust Law Section Spring Meeting, Washington, DC (April 2022)
  • Navigating Recent Developments in Global Merger Enforcement — Dechert Webinar (October 2020)
  • Should Antitrust Tame the Global Tech Giants? — ABA Section of Antitrust Law Spring Meeting, Washington, DC (April 2019) 
  • State Boards and Professional Licensing Post-NC Dental — American Health Lawyers Association/ABA Section of Antitrust Law Antitrust in Health Care Conference, Arlington, VA (May 2018)
  • Whose Internet Is It Anyway? — ABA Section of Antitrust Law Spring Meeting, Washington, DC (March 2018)
  • Noerr-Pennington and the FTC — ABA Section of Antitrust Law Exemptions & Immunities Committee Program, Washington, DC (January 2018)
  • The FTC’s New Section 5 Policy Statement: A Step Forward? — ABA Section of Antitrust Law Unilateral Conduct Committee Program, Washington, DC (September 2015)
  • Reflections on the Supreme Court’s North Carolina Dental Decision — Citizen Advocacy Center Event, Washington, DC (June 2015)
  • Fundamentals of Antitrust Exemptions and Immunities — ABA Section of Antitrust Law Exemptions & Immunities Committee Program, Washington, DC (May 2014)
  • Healthcare Antitrust: Physician Contracting and Joint Ventures — 2013 Southeast Healthcare Provider Conference, Charlotte, NC (September 2013)
  • Insurance and Other New Antitrust Targets: The Politics and Legislative Process of Antitrust Exemptions and Immunities — ABA Section of Antitrust Law Spring Meeting, Washington, DC (April 2010)
  • Does Telecom Have a Future? — Supernova 2008: Challenges for the Network Age, San Francisco, CA (June 2008)
  • Net Neutrality and the Future of the Internet — ABA Annual Meeting, San Francisco, CA (August 2007)


Services Industries
    • University of Virginia, B.A., Economics, 1994, high distinction
    • University of Virginia School of Law, J.D., 1999, Virginia Tax Review
    • District of Columbia
    • New York
    • Supreme Court of the United States
    • ABA Section of Antitrust Law
      • Co-Chair, Committee Operations (2022-present)
      • Vice-Chair, U.S. Comments & Policy Committee (2021-2022)     
      • Editorial Board Member, Antitrust Law Developments 9 (2020-2022)
      • Member, Long Range Planning Committee (2020-2021)
      • Co-Chair, Media & Technology Committee (2015 – 2020)
      • Chair, Exemptions & Immunities Committee (2013-2015)
      • Vice-Chair, Exemptions & Immunities Committee (2007-2012)
      • Vice-Chair, Programs Committee (2004-2007)
      • Member, Editorial Board, Annual Review of Antitrust Law Developments (2002-2004)